Boston Scientific Corporation (BSX)
Company Info
Highlights
$155.14B
$1.37
76.54
2.58
$17.55B
$11.79B
$4.09B
$71.88 - $107.17
$116.78
1.06%
1.55
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Boston Scientific Corporation (BSX) returned 18.72% year-to-date (YTD) and 42.24% over the past 12 months. Over the past 10 years, BSX delivered an annualized return of 19.38%, outperforming the S&P 500 benchmark at 10.87%.
BSX
18.72%
11.33%
21.90%
42.24%
25.01%
19.38%
^GSPC (Benchmark)
1.30%
12.94%
1.49%
12.48%
15.82%
10.87%
Monthly Returns
The table below presents the monthly returns of BSX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 14.60% | 1.40% | -2.80% | 1.97% | 3.08% | 18.72% | |||||||
| 2024 | 9.43% | 4.66% | 3.44% | 4.94% | 5.15% | 1.91% | -4.06% | 10.71% | 2.46% | 0.26% | 7.90% | -1.48% | 54.51% |
| 2023 | -0.04% | 1.02% | 7.08% | 4.18% | -1.23% | 5.07% | -4.14% | 4.03% | -2.11% | -3.05% | 9.18% | 3.44% | 24.94% |
| 2022 | 0.99% | 2.96% | 0.27% | -4.92% | -2.61% | -9.12% | 10.14% | -1.80% | -3.92% | 11.31% | 5.01% | 2.21% | 8.92% |
| 2021 | -1.42% | 9.42% | -0.34% | 12.81% | -2.41% | 0.49% | 6.64% | -0.99% | -3.90% | -0.60% | -11.73% | 11.58% | 18.16% |
| 2020 | -7.41% | -10.70% | -12.73% | 14.86% | 1.36% | -7.58% | 9.85% | 6.35% | -6.85% | -10.31% | -3.27% | 8.45% | -20.50% |
| 2019 | 7.95% | 5.16% | -4.34% | -3.28% | 3.48% | 11.90% | -1.21% | 0.64% | -4.77% | 2.48% | 3.72% | 4.55% | 27.96% |
| 2018 | 12.79% | -2.50% | 0.22% | 5.12% | 5.81% | 7.60% | 2.78% | 5.80% | 8.27% | -6.13% | 4.23% | -6.19% | 42.56% |
| 2017 | 11.23% | 2.04% | 1.30% | 6.07% | 2.46% | 2.55% | -3.97% | 3.49% | 5.88% | -3.53% | -6.61% | -5.67% | 14.61% |
| 2016 | -4.93% | -3.14% | 10.78% | 16.53% | 3.60% | 2.91% | 3.89% | -1.89% | -0.08% | -7.56% | -7.00% | 5.72% | 17.30% |
| 2015 | 11.77% | 14.11% | 5.03% | 0.39% | 2.53% | -3.12% | -2.03% | -3.46% | -1.97% | 11.40% | -0.00% | 0.88% | 39.17% |
| 2014 | 12.56% | -3.18% | 3.21% | -6.73% | 1.74% | -0.47% | 0.08% | -0.78% | -6.86% | 12.45% | -3.09% | 2.95% | 10.23% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 94, BSX is among the top 6% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Boston Scientific Corporation (BSX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Boston Scientific Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Boston Scientific Corporation was 89.15%, occurring on Jul 26, 2012. Recovery took 2268 trading sessions.
The current Boston Scientific Corporation drawdown is 0.13%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -89.15% | Apr 6, 2004 | 2093 | Jul 26, 2012 | 2268 | Aug 2, 2021 | 4361 |
| -73.66% | Jul 19, 1999 | 353 | Dec 6, 2000 | 570 | Mar 20, 2003 | 923 |
| -58.38% | Jan 27, 1993 | 177 | Oct 7, 1993 | 361 | Mar 14, 1995 | 538 |
| -47.77% | Aug 20, 1998 | 57 | Nov 9, 1998 | 89 | Mar 19, 1999 | 146 |
| -46.02% | Aug 7, 1997 | 95 | Dec 19, 1997 | 134 | Jul 6, 1998 | 229 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Boston Scientific Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Boston Scientific Corporation, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 11.5% positive surprise.
Valuation
The Valuation section provides an overview of how Boston Scientific Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for BSX, comparing it with other companies in the Medical Devices industry. Currently, BSX has a P/E ratio of 76.5. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for BSX compared to other companies in the Medical Devices industry. BSX currently has a PEG ratio of 2.6. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BSX relative to other companies in the Medical Devices industry. Currently, BSX has a P/S ratio of 8.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BSX in comparison with other companies in the Medical Devices industry. Currently, BSX has a P/B value of 7.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |